Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA-AF-Japan): One-year safety and effectiveness analyses.

Takeshi YamashitaYukihiro KoretsuneTomoko NagaoKazuhito Shiosakai

Published in: Journal of arrhythmia (2020)

At one-year follow-up, the results showed no major concerns about the safety and effectiveness of edoxaban in Japanese patients with NVAF in a real-world clinical setting.

Keyphrases

atrial fibrillation
randomized controlled trial
systematic review
venous thromboembolism
oral anticoagulants
left atrial appendage
public health
heart failure
left atrial
catheter ablation
left ventricular
coronary artery disease
acute coronary syndrome
mitral valve